Neuropeptide FF receptors have opposing modulatory effects on nociception

Journal of Pharmacology and Experimental Therapeutics

Volumn 334, Issue 1, 2010, Pages 244-254

  Lameh, Jelveh ^a   Bertozzi, Fabio ^a   Kelly, Nicholas ^a   Jacobi, Paula M ^a   Nguyen, Derek ^a   Bajpai, Abhishek ^a   Gaubert, Gilles ^a   Olsson, Roger ^a   Gardell, Luis R ^a  

^a ACADIA PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AC 262616; AC 262620; AC 262970; AC 263093; DANSYL PROLYLGLUTAMYLARGININAMIDE; FORMALDEHYDE; N(2) (DIPHENYLACETYL) N [(4 HYDROXYPHENYL)METHYL]ARGININAMIDE; NEUROPEPTIDE AF; NEUROPEPTIDE FF; NEUROPEPTIDE FF1 RECEPTOR; NEUROPEPTIDE FF2 RECEPTOR; NEUROPEPTIDE RECEPTOR; OPIATE AGONIST; OPIATE ANTAGONIST; UNCLASSIFIED DRUG;

ALLODYNIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HYPERALGESIA; HYPERSENSITIVITY; INFLAMMATION; MALE; MECHANICAL STIMULATION; NEUROPATHIC PAIN; NOCICEPTION; NONHUMAN; PAIN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLIC AMP; DISEASE MODELS, ANIMAL; HYPERALGESIA; LIGANDS; MALE; MICE; MONONEUROPATHIES; NIH 3T3 CELLS; OLIGOPEPTIDES; PAIN MEASUREMENT; PAIN THRESHOLD; RATS; RECEPTORS, NEUROPEPTIDE; SMALL MOLECULE LIBRARIES; TRANSFECTION;

EID: 77953791637     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.109.164384     Document Type: Article

References (39)

1. Altier N, Dray A, Ménard D, and Henry JL (2000) Neuropeptide FF attenuates allodynia in models of chronic inflammation and neuropathy following intrathecal or intracerebroventricular administration. Eur J Pharmacol 407:245-255.
2. Ballet S, Braz J, Mauborgne A, Bourgoin S, Zajac JM, Hamon M, and Cesselin F (2002) The neuropeptide FF analogue, 1DMe, reduces in vivo dynorphin release from the rat spinal cord. J Neurochem 81:659-662.
3. Bonini JA, Jones KA, Adham N, Forray C, Artymyshyn R, Durkin MM, Smith KE, Tamm JA, Boteju LW, Lakhlani PP, et al. (2000) Identification and characterization of two G protein-coupled receptors for neuropeptide FF. J Biol Chem 275: 39324-39331.
4. Burgess SE, Gardell LR, Ossipov MH, Malan TP Jr, Vanderah TW, Lai J, and Porreca F (2002) Time-dependent descending facilitation from the rostral ventromedial medulla maintains, but does not initiate, neuropathic pain. J Neurosci 22:5129-5136.
5. Burstein ES, Spalding TA, and Brann MR (1997) Pharmacology of muscarinic receptor subtypes constitutively activated by G proteins. Mol Pharmacol 51:312-319.
6. Doods HN, Wienen W, Entzeroth M, Rudolf K, Eberlein W, Engel W, and Wieland HA (1995) Pharmacological characterization of the selective nonpeptide neuropeptide Y Y1 receptor antagonist BIBP 3226. J Pharmacol Exp Ther 275:136-142.
7. Dubner R and Ruda MA (1992) Activity-dependent neuronal plasticity following tissue injury and inflammation. Trends Neurosci 15:96-103.
8. Dupouy V and Zajac JM (1995) Effects of neuropeptide FF analogs on morphine analgesia in the nucleus raphe dorsalis. Regul Pept 59:349-356.
9. Elshourbagy NA, Ames RS, Fitzgerald LR, Foley JJ, Chambers JK, Szekeres PG, Evans NA, Schmidt DB, Buckley PT, Dytko GM, et al. (2000) Receptor for the pain modulatory neuropeptides FF and AF is an orphan G protein-coupled receptor. J Biol Chem 275:25965-25971.
10. Fang Q, Guo J, He F, Peng YL, Chang M, and Wang R (2006) In vivo inhibition of neuropeptide FF agonism by BIBP3226, an NPY Y1 receptor antagonist. Peptides 27:2207-2213.
11. Gardell LR, Ibrahim M, Wang R, Wang Z, Ossipov MH, Malan TP Jr, Porreca F, and Lai J (2004) Mouse strains that lack spinal dynorphin upregulation after peripheral nerve injury do not develop neuropathic pain. Neuroscience 123:43-52.
12. Gardell LR, Vanderah TW, Gardell SE, Wang R, Ossipov MH, Lai J, and Porreca F (2003) Enhanced evoked excitatory transmitter release in experimental neuropathy requires descending facilitation. J Neurosci 23:8370-8379. (Pubitemid 37129654)
13. Gardell LR, Wang R, Burgess SE, Ossipov MH, Vanderah TW, Malan TP Jr, Lai J, and Porreca F (2002) Sustained morphine exposure induces a spinal dynorphin-dependent enhancement of excitatory transmitter release from primary afferent fibers. J Neurosci 22:6747-6755.
14. Gaubert G, Bertozzi F, Kelly NM, Pawlas J, Scully AL, Nash NR, Gardell LR, Lameh J, and Olsson R (2009) Discovery of selective nonpeptidergic neuropeptide FF2 receptor agonists. J Med Chem 12:6511-6514.
15. Gicquel S, Mazarguil H, Allard M, Simonnet G, and Zajac JM (1992) Analogues of F8Famide resistant to degradation, with high affinity and in vivo effects. Eur J Pharmacol 222:61-67.
16. Gouardères C, Jhamandas K, Sutak M, and Zajac JM (1996) Role of opioid receptors in the spinal antinociceptive effects of neuropeptide FF analogues. Br J Pharmacol 117:493-501. (Pubitemid 26056859)
17. Kersanté F, Mollereau C, Zajac JM, and Roumy M (2006) Anti-opioid activities of NPFF1 receptors in a SH-SY5Y model. Peptides 27:980-989.
18. Kim SH and Chung JM (1992) An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain 50:355-363.
19. Kontinen VK, Aarnisalo AA, Idänpään-Heikkilä JJ, Panula P, and Kalso E (1997) Neuropeptide FF in the rat spinal cord during carrageenan inflammation. Peptides 18:287-292.
20. 2-adrenergic and μ-opioid spinal antinociception by neuropeptide FF. Peptides 16:973-977.
21. Kotani M, Mollereau C, Detheux M, Le Poul E, Brézillon S, Vakili J, Mazarguil H, Vassart G, Zajac JM, and Parmentier M (2001) Functional characterization of a human receptor for neuropeptide FF and related peptides. Br J Pharmacol 133: 138-144.
22. Kovelowski CJ, Ossipov MH, Sun H, Lai J, Malan TP, and Porreca F (2000) Supraspinal cholecystokinin may drive tonic descending facilitation mechanisms to maintain neuropathic pain in the rat. Pain 87:265-273.
23. Lake JR, Hammond MV, Shaddox RC, Hunsicker LM, Yang HY, and Malin DH (1991) IgG from neuropeptide FF antiserum reverses morphine tolerance in the rat. Neurosci Lett 132:29-32.
24. Liu Q, Guan XM, Martin WJ, McDonald TP, Clements MK, Jiang Q, Zeng Z, Jacobson M, Williams DL Jr, Yu H, et al. (2001) Identification and characterization of novel mammalian neuropeptide FF-like peptides that attenuate morphine-induced antinociception. J Biol Chem 276:36961-36969.
25. Lombard MC, Simonnet G, Zajac JM, Besson JM, and Allard M (1995) Distribution of neuropeptide FF (FLFQPQRFamide) receptors in the adult rat spinal cord: effects of dorsal rhizotomy and neonatal capsaicin. Neuroscience 68:1229-1235.
26. 1 receptor antagonists. Eur J Pharmacol 451:245-256.
27. Oberling P, Stinus L, Le Moal M, and Simonnet G (1993) Biphasic effect on nociception and antiopiate activity of the neuropeptide FF (FLFQPQRFamide) in the rat. Peptides 14:919-924.
28. Ossipov MH, Zhang ET, Carvajal C, Gardell L, Quirion R, Dumont Y, Lai J, and Porreca F (2002) Selective mediation of nerve injury-induced tactile hypersensitivity by neuropeptide Y. J Neurosci 22:9858-9867. (Pubitemid 35332870)
29. Porreca F, Burgess SE, Gardell LR, Vanderah TW, Malan TP Jr, Ossipov MH, Lappi DA, and Lai J (2001) Inhibition of neuropathic pain by selective ablation of brainstem medullary cells expressing the μ-opioid receptor. J Neurosci 21:5281-5288.
30. Prokai L, Prokai-Tatrai K, Zharikova A, Li X, and Rocca JR (2001) Combinatorial lead optimization of a neuropeptide FF antagonist. J Med Chem 44:1623-1626.
31. Prokai L, Zharikova AD, Janáky T, and Prokai-Tatrai K (2000) Exploratory pharmacokinetics and brain distribution study of a neuropeptide FF antagonist by liquid chromatography/atmospheric pressure ionization tandem mass spectrometry. Rapid Commun Mass Spectrom 14:2412-2418.
32. Simonin F, Schmitt M, Laulin JP, Laboureyras E, Jhamandas JH, MacTavish D, Matifas A, Mollereau C, Laurent P, Parmentier M, et al. (2006) RF9, a potent and selective neuropeptide FF receptor antagonist, prevents opioid-induced tolerance associated with hyperalgesia. Proc Natl Acad Sci USA 103:466-471.
33. Vanderah TW, Gardell LR, Burgess SE, Ibrahim M, Dogrul A, Zhong CM, Zhang ET, Malan TP Jr, Ossipov MH, Lai J, et al. (2000) Dynorphin promotes abnormal pain and spinal opioid antinociceptive tolerance. J Neurosci 20:7074-7079.
34. Wang Z, Gardell LR, Ossipov MH, Vanderah TW, Brennan MB, Hochgeschwender U, Hruby VJ, Malan TP Jr, Lai J, and Porreca F (2001) Pronociceptive actions of dynorphin maintain chronic neuropathic pain. J Neurosci 21:1779-1786.
35. Wei H, Panula P, and Pertovaara A (2001) Modulation of pain by [1DMe]NPYF, a stable analogue of neuropeptide FF, in neuropathic rats. Brain Res 900:234-243.
36. Xie JY, Herman DS, Stiller CO, Gardell LR, Ossipov MH, Lai J, Porreca F, and Vanderah TW (2005) Cholecystokinin in the rostral ventromedial medulla mediates opioid-induced hyperalgesia and antinociceptive tolerance. J Neurosci 25: 409-416.
37. Xu M, Kontinen VK, Panula P, and Kalso E (1999) Effects of (1DMe)NPYF, a synthetic neuropeptide FF analogue, in different pain models. Peptides 20:1071-1077.
38. Yang HY and Iadarola MJ (2006) Modulatory roles of the NPFF system in pain mechanisms at the spinal level. Peptides 27:943-952.
39. Yang HY, Tao T, and Iadarola MJ (2008) Modulatory role of neuropeptide FF system in nociception and opiate analgesia. Neuropeptides 42:1-18.